| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 343.00 | 8.2% | 13.6% |
| Total Income | 343.00 | 8.2% | 13.6% |
| Expenditure | 183.00 | 1.7% | 20.4% |
| PBT | 160.00 | 39.1% | 158.1% |
| Net Profit | 122.00 | 37.1% | 577.8% |
| OPM | 46.65% | 3.43pp | 22.81pp |
| NPM | 35.57% | 7.49pp | 29.61pp |
| EPS | 1.02 | 43.7% | 580.0% |
Indivior Reports Q2 2026 Results and Raises Full-Year Guidance
03 Aug 2026 · 3 Aug, 4:26 pm
Summary
Indivior Pharmaceuticals, Inc. reported strong financial results for the second quarter of 2026, with total net revenue reaching $343 million, a 14% increase year-over-year, driven by record SUBLOCADE net revenue of $253 million. The company also achieved record quarterly net income and Adjusted EBITDA, with the latter growing 111% year-over-year to $186 million. Based on this performance, Indivior has raised its full-year 2026 financial guidance, anticipating significant growth in both total SUBLOCADE net revenue and Adjusted EBITDA.
Key Highlights
- 1
Indivior reported Q2'26 total net revenue of $343 million, an increase of 14% year-over-year.
- 2
Record quarterly total SUBLOCADE® net revenue reached $253 million in Q2'26, up 21% year-over-year.
- 3
The company achieved record quarterly GAAP net income of $122 million and record non-GAAP net income of $142 million in Q2'26.
- 4
Record quarterly Adjusted EBITDA of $186 million was reported for Q2'26, representing an 111% increase year-over-year.
- 5
Indivior raised its full-year 2026 guidance, now expecting total SUBLOCADE net revenue growth of 20% year-over-year and adjusted EBITDA growth of 68% year-over-year.
- 6
Approximately 4.7 million shares were repurchased in Q2'26 for $175 million as part of capital deployment.
Management Comments
Joe Ciaffoni
Exceptional operational execution in Phase II – Accelerate – of the Indivior Action Agenda fueled strong SUBLOCADE performance in the quarter and is the primary driver of our raised 2026 guidance. We remain focused on Phase II – Accelerate – for the remainder of 2026 and look forward to closing our proposed merger with Supernus, which is expected in the fourth quarter. Upon the close of our proposed merger, all three Phases of the Indivior Action Agenda will have been successfully completed.
Ryan Preblick
We delivered record SUBLOCADE net revenue and adjusted EBITDA in the quarter leading us to raise our 2026 guidance. We now expect 2026 total SUBLOCADE net revenue growth of 20% year-over-year and adjusted EBITDA growth of 68% year-over-year at the midpoint of our guidance ranges. We returned capital to our shareholders through the repurchase of $175 million in shares during the quarter. We are committed to creating long-term shareholder value.
Informational and educational content only. Not investment advice.